Interferon alfa-2a biosimilar (BioGeneric Pharma)

干扰素α-2a生物类似药 (BioGeneric Pharma)

Report date: 2022/01/24 10:09:36

Base Information

Drug NameInterferon alfa-2a biosimilar (BioGeneric Pharma)
Drug Alias Name干扰素α-2a生物仿制药 (BioGeneric Pharma)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEgypt
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiogeneric Pharma
China Registration ClassN/A

Develop Information

Active CompaniesBiogeneric Pharma
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB04
Related LinksN/A